Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2107220 | 0.95 | NPSR1 (0.42) | NPSR1TSHRRXFP1SIRT2HDAC3 | |
| SCHEMBL28661871 | 0.93 | NPSR1 (0.39) | NPSR1TSHRRXFP1SIRT2HDAC3 | |
| SCHEMBL30467245 | 0.93 | NPSR1 (0.39) | NPSR1TSHRRXFP1SIRT2HDAC3 | |
| SCHEMBL7653830 | 0.88 | SIRT2 (0.38) | NPSR1TSHRRXFP1SIRT2HDAC3 | |
| SCHEMBL29361802 | 0.87 | SIRT2 (0.45) | NPSR1TSHRRXFP1SIRT2HDAC3 | |
| SCHEMBL16765694 | 0.87 | SIRT2 (0.45) | NPSR1TSHRRXFP1SIRT2HDAC3 | |
| SCHEMBL44480 | 0.87 | SIRT2 (0.45) | NPSR1TSHRRXFP1SIRT2HDAC3 | |
| SCHEMBL27529584 | 0.86 | SIRT2 (0.44) | NPSR1TSHRRXFP1SIRT2HDAC3 | |
| SCHEMBL1395479 | 0.82 | POLB (0.49) | NPSR1TSHRRXFP1SIRT2HDAC3 | |
| SCHEMBL29544944 | 0.81 | SIRT2 (0.49) | NPSR1TSHRRXFP1SIRT2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0569086-A2 | Method and kit for attaching compounds to carboxylated substrates using uronium salt | Johnson & Johnson Clinical Diagnostics, Inc. (US) | 1993-11-10 | — | — | EP | claimed |
| EP-2074096-B1 | 3-PYRIDINECARBOXAMIDE AND 2-PYRAZINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | HOFFMANN LA ROCHE (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-8188093-B2 | Pyrazinecarboxamide derivatives as HDL-cholesterol raising agents | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2450350-A1 | 3-Pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents | F. Hoffmann-La Roche AG (CH) | 2012-05-09 | — | — | EP | disclosed |
| EP-2066636-B1 | 5-PHENYL-NICOTINAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-10-26 | — | — | EP | disclosed |
| US-20110082075-A1 | Anti-viral fusion peptides | PRENDERGAST KENNETH FRANCIS | 2011-04-07 | — | — | US | disclosed |
| US-20100267745-A1 | 3-Pyridinecarboxamide Derivatives as HDL-Cholesterol Raising Agents | ANDJELKOVIC MIRJANA | 2010-10-21 | — | — | US | disclosed |
| US-7812028-B2 | 3-pyridinecarboxamide derivatives as HDL-cholesterol raising agents | HOFFMANN-LA ROCHE INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7781593-B2 | CB1 cannabinoid receptor antagonists/inverse agonists; 5-(4-chloro-phenyl)-N-((1R,2R)-2-hydroxy-cyclohexyl)-6-(3-methoxy-propyl)-nicotinamide for example; eating disorders, obesity, diabetes type II or non insulin dependent diabetes (NIDD), neuroinflammation, diarrhea, drug abuse | HOFFMANN-LA ROCHE INC. (US) | 2010-08-24 | — | — | US | disclosed |
| EP-2074096-A1 | 3-PYRIDINECARBOXAMIDE AND 2-PYRAZINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| EP-2066636-A1 | 5-PHENYL-NICOTINAMIDE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| US-20090143409-A1 | 3-PYRIDINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | ANDJELKOVIC MIRJANA | 2009-06-04 | — | — | US | disclosed |
| US-20080085906-A1 | 3-Pyridinecarboxamide derivatives as HDL-cholesterol raising agents | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-10 | — | — | US | disclosed |
| WO-2008040651-A1 | 3-PYRIDINECARBOXAMIDE AND 2-PYRAZINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-10 | — | — | WO | disclosed |
| US-20080070931-A1 | CB1 cannabinoid receptor antagonists/inverse agonists; 5-(4-chloro-phenyl)-N-((1R,2R)-2-hydroxy-cyclohexyl)-6-(3-methoxy-propyl)-nicotinamide for example; eating disorders, obesity, diabetes type II or non insulin dependent diabetes (NIDD), neuroinflammation, diarrhea, drug abuse | HOFFMANN-LA ROCHE INC. | 2008-03-20 | — | — | US | disclosed |
| WO-2008031734-A1 | 5-PHENYL-NICOTINAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-20 | — | — | WO | disclosed |
| EP-0569086-A2 | Method and kit for attaching compounds to carboxylated substrates using uronium salt | Johnson & Johnson Clinical Diagnostics, Inc. (US) | 1993-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085906-A1 | 3-Pyridinecarboxamide derivatives as HDL-cholesterol raising agents | CETP, APOB, LDLR | NPSR1 727/4885TSHR 427/4885RXFP1 164/4885 |
| US-20080070931-A1 | CB1 cannabinoid receptor antagonists/inverse agonists; 5-(4-chloro-phenyl)-N-((1R,2R)-2-hydroxy-cyclohexyl)-6-(3-methoxy-propyl)-nicotinamide for example; eating disorders, obesity, diabetes type II or non insulin dependent diabetes (NIDD), neuroinflammation, diarrhea, drug abuse | CNR2, CNR1, GPR119 | NPSR1 87/4885TSHR 476/4885RXFP1 215/4885 |
| US-20090143409-A1 | 3-PYRIDINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | CETP, APOB, LDLR | NPSR1 727/4885TSHR 427/4885RXFP1 164/4885 |
| US-20110082075-A1 | Anti-viral fusion peptides | AEBP2, CNBP, HAVCR2 | NPSR1 2223/4885TSHR 3463/4885RXFP1 975/4885 |
| US-20100267745-A1 | 3-Pyridinecarboxamide Derivatives as HDL-Cholesterol Raising Agents | CETP, APOB, LDLR | NPSR1 727/4885TSHR 427/4885RXFP1 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.